Drugs / AXS-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02746068 | Mar 2016 → Dec 2020 | osteoarthritis, knee | Axsome Therapeutics, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-01-09 | Axsome Therapeutics, Inc. | Results Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial gcs-web.com ↗
The IDMC has recommended that the COAST-1 trial be continued to full enrollment, and that the CREATE-1 trial be stopped for futility. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-01-09 | Axsome Therapeutics, Inc. | Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial gcs-web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXS-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02746068 ↗ |
| Known as | Disodium Zoledronate Tetrahydrate | “COAST -1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study. A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium...” NCT02746068 ↗ |
| Route | Oral | “Administered orally in the morning for 6 weeks” NCT02746068 ↗ |